Vir Biotechnology CEO George Scangos' 2021 pay jumps 1,979% to $21M
Vir Biotechnology reports 2021 executive compensation
By ExecPay News
Published: April 7, 2022
Vir Biotechnology reported fiscal year 2021 executive compensation information on April 7, 2022.
In 2021, five executives at Vir Biotechnology received on average a compensation package of $8.7M, a 546% increase compared to previous year.
Average pay of disclosed executives at Vir Biotechnology
George Scangos, Chief Executive Officer, received $21M in total, which increased by 1,979% compared to 2020. 59% of Scangos' compensation, or $12M, was in option awards. Scangos also received $487K in non-equity incentive plan, $575K in salary, $7.5M in stock awards, as well as $12K in other compensation.
Phillip Pang, Chief Medical Officer, received a compensation package of $6.4M. 54% of the compensation package, or $3.5M, was in option awards.
Herbert Skip Virgin, Chief Scientific Officer, earned $6.4M in 2021, a 480% increase compared to previous year.
Howard Horn, Chief Financial Officer, received $5.1M in 2021, which increases by 214% compared to 2020.
Ann Aine Hanly, Chief Technology Officer, earned $4.7M in 2021.
Related executives
You may also like
Source: SEC filing on April 7, 2022.